Datafarm Announces the Release of Web-Based eCTD Viewer
Datafarm announces the release of a simple and cost effective Web-based eCTD viewer for companies of all sizes.
Philadelphia, 19 June 2006-Datafarm, the leading provider of electronic regulatory submission solutions, today announced the availability of eCTDViewer® Web Edition Version 3.0. This Web-based eCTD viewing solution includes support for all recent eCTD specifications and guidelines published by ICH, FDA, EMEA (including the most recent v1.2 specifications), Japan, Health Canada and Taiwanese agencies. This business tool offers zero desktop footprint and is designed meet the needs of companies of all sizes.
eCTDViewer Web Edition is built upon recognized technology standards such as HTML, XML, and JAVA. This combination of cross-platform technologies makes the application easy to deploy on both Windows and Linux servers, and allows it to support multiple application servers such as BEA WebLogic and Apache Tomcat. By using this standards-based approach, Datafarm has made it possible for any organization, regardless of size, to seamlessly incorporate eCTDViewer® Web Edition into their existing environment.
Datafarm's eCTD suite of applications includes eCTDBuilder®, used for submission compilation, and eCTDViewer® for submission review and paper dossier creation. This suite is currently used by over 40 companies in the US, EU, Canada and Japan who have successfully submitted over 800 submissions to the regulatory authorities.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
